Luo Qixun, Zhu Zunwei, Wan Lisong
Department of Critical Care Medicine, Sir Run Run Shaw Hospital, Affiliated with the Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Department of Urology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi, China.
Transplant Proc. 2025 Jul-Aug;57(6):1180-1186. doi: 10.1016/j.transproceed.2025.05.028. Epub 2025 Jun 26.
To investigate and validate the protective role of plumbagin (PL) in renal ischemia-reperfusion injury (IRI) by mediating the Nrf2/HO-1 pathway and reducing renal function damage, thereby providing a theoretical basis for the application of PL in the prevention of renal IRI.
Twenty-four healthy adult male BALB/c mice were randomly divided into four groups: the sham group, the IR model group (IRI group), the IRI + PL 10 mg/kg group, and the IRI + PL 10 mg/kg + ML385 (30 mg/kg) group. Four groups of mice were given drugs 2 weeks before modeling, for 2 consecutive weeks (once a day), and the modeling was started 1 hour after the administration on the 14th day. In the sham operation group, only the renal vessels were isolated without clamping ischemia, and in the other groups, minimally invasive artery clamps were used to establish the mouse RIRI injury model. Serum creatinine (Scr), blood urea nitrogen (BUN), interleukin-6 (IL-6), myeloperoxidase (MPO), serum superoxide dismutase (SOD), GSH-Px, malondialdehyde (MDA), and inflammatory levels of mice in each group were detected and analyzed; pathological examination of renal tissue injury; and the expressions of Nrf-2 and HO-1 were detected by Western blotting.
Compared with the sham group, the IRI group showed elevated Scr, BUN, IL-6, MDA, and MPO levels, reduced SOD and GSH-Px activities, severe renal injury, and decreased Nrf-2/HO-1 expression. PL administration reduced renal injury, decreased Scr, BUN, IL-6, MDA, and MPO levels, increased SOD and GSH-Px levels, and increased Nrf-2/HO-1 expression, as confirmed by pathology and Western blotting.
PL can reduce the level of oxidative stress and the release of inflammatory factors by regulating the Nrf-2/HO-1 signaling pathway, improve renal injury induced by ischemia/reperfusion in mice, and play a renoprotective role.
探讨并验证白花丹醌(PL)通过介导Nrf2/HO-1信号通路减轻肾功能损害,在肾缺血再灌注损伤(IRI)中的保护作用,为PL在预防肾IRI中的应用提供理论依据。
将24只健康成年雄性BALB/c小鼠随机分为四组:假手术组、IR模型组(IRI组)、IRI + PL 10 mg/kg组和IRI + PL 10 mg/kg + ML385(30 mg/kg)组。四组小鼠在造模前两周给药,连续给药2周(每天一次),第14天给药1小时后开始造模。假手术组仅分离肾血管,不夹闭缺血,其他组采用微创动脉夹建立小鼠RIRI损伤模型。检测并分析各组小鼠血清肌酐(Scr)、血尿素氮(BUN)、白细胞介素-6(IL-6)、髓过氧化物酶(MPO)、血清超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)、丙二醛(MDA)及炎症水平;对肾组织损伤进行病理检查;采用蛋白质免疫印迹法检测Nrf-2和HO-1的表达。
与假手术组相比,IRI组Scr、BUN、IL-6、MDA和MPO水平升高,SOD和GSH-Px活性降低,肾损伤严重,Nrf-2/HO-1表达降低。病理学和蛋白质免疫印迹法证实,PL给药减轻了肾损伤,降低了Scr、BUN、IL-6、MDA和MPO水平,提高了SOD和GSH-Px水平,增加了Nrf-2/HO-1表达。
PL可通过调节Nrf-2/HO-1信号通路降低氧化应激水平和炎症因子释放,改善小鼠缺血/再灌注诱导的肾损伤,发挥肾脏保护作用。